Page 11234

Archive for the ‘Global News Feed’ Category

BioCryst to Present at Upcoming Virtual Investment Conferences

Sunday, November 22nd, 2020

RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Evercore ISI 3rd Annual HealthCONx on Wednesday, December 2, 2020 at 12:35 p.m. ET and at the Piper Sandler 32nd Annual Healthcare Conference. Both conferences are being conducted as virtual events.

Continued here:
BioCryst to Present at Upcoming Virtual Investment Conferences

Read More...

BioRestorative Therapies Emerges from Chapter 11 Reorganization

Sunday, November 22nd, 2020

MELVILLE, N.Y., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, announced today that its amended joint plan of reorganization has become effective and it has emerged from Chapter 11 reorganization. Pursuant to the confirmed plan of reorganization, the Company has received $3,848,000 in financing. The confirmed plan of reorganization also provides for additional funding, subject to certain conditions, of $3,500,000 less the sum of the debtor-in-possession financing provided to the Company during the reorganization (approximately $1,227,000) and the costs incurred by the debtor-in-possession lender.

More:
BioRestorative Therapies Emerges from Chapter 11 Reorganization

Read More...

Trevena, Inc. Announces Publication Highlighting GI Tolerability Profile of OLINVYK™ (oliceridine) injection in Pain and Therapy

Sunday, November 22nd, 2020

--OLINVYK significantly reduced risk of vomiting and rescue antiemetic use compared to IV morphine in a retrospective analysis

Originally posted here:
Trevena, Inc. Announces Publication Highlighting GI Tolerability Profile of OLINVYK™ (oliceridine) injection in Pain and Therapy

Read More...

Zealand Pharma increases its share capital as a consequence of exercise of employee warrants

Sunday, November 22nd, 2020

Company announcement – No. 55 / 2020

More here:
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants

Read More...

Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day

Sunday, November 22nd, 2020

- SPEARHEAD-1 enrolment on track; planning to launch ADP-A2M4 in 2022 in the US for people with synovial sarcoma -

Read the original here:
Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day

Read More...

New Test for Triaging Preeclampsia Passes Key Development Milestone: Progenity Releases Prospective Clinical Verification Data for its Preecludia™…

Sunday, November 22nd, 2020

High sensitivity and high negative predictive value (NPV) observed for ruling out the risk of preeclampsia High sensitivity and high negative predictive value (NPV) observed for ruling out the risk of preeclampsia

Read more:
New Test for Triaging Preeclampsia Passes Key Development Milestone: Progenity Releases Prospective Clinical Verification Data for its Preecludia™...

Read More...

Harrow Health Announces Participation at the Piper Sandler 32nd Annual Healthcare Conference

Sunday, November 22nd, 2020

NASHVILLE, Tenn., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that Mark Baum, Harrow’s Chief Executive Officer, and Andrew Boll, Harrow’s Chief Financial Officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place December 1 – 3, 2020.

View original post here:
Harrow Health Announces Participation at the Piper Sandler 32nd Annual Healthcare Conference

Read More...

Todos Medical Announces Positive In Vitro Data for Tollovid™ Confirming 3CL Protease Inhibition Mechanism of Action

Sunday, November 22nd, 2020

NEW YORK, NY, REHOVAT, ISRAEL, SINGAPORE, Nov. 20, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire  -- Todos Medical (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced positive in vitro data by its joint venture partner NLC Pharma for the Company’s dietary supplement Tollovid™, demonstrating its ability to inhibit the 3CL protease. The 3CL protease is an enzyme that is required for the intracellular replication of coronaviruses. Tollovid received a certificate of free sale from the FDA in August 2020 and is being launched commercially into the US market initially at botanical wellness store The Alchemist’s Kitchen™ in New York City.

Originally posted here:
Todos Medical Announces Positive In Vitro Data for Tollovid™ Confirming 3CL Protease Inhibition Mechanism of Action

Read More...

Black Diamond Therapeutics Provides Update on GBM Program and Presents Pre-Clinical Data at the 2020 SNO Annual Meeting

Sunday, November 22nd, 2020

CAMBRIDGE, Mass. and NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) --  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the nomination of BDTX-1535 as the Company’s development candidate for the treatment of glioblastoma multiforme (GBM), as well as the commencement of Investigational New Drug (IND)-enabling studies.

Excerpt from:
Black Diamond Therapeutics Provides Update on GBM Program and Presents Pre-Clinical Data at the 2020 SNO Annual Meeting

Read More...

Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

Sunday, November 22nd, 2020

MALVERN, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.

See the article here:
Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

Read More...

Aditxt Appoints Anthony Voorhies as Head of Business Development for AditxtScore™

Sunday, November 22nd, 2020

Voorhies has Extensive Business and Industry Experience in Diagnostics & Monitoring

See the original post:
Aditxt Appoints Anthony Voorhies as Head of Business Development for AditxtScore™

Read More...

Chiasma to Host an Expert Panel on Acromegaly and the MPOWERED® Phase 3 Trial Results

Sunday, November 22nd, 2020

NEEDHAM, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injections, today announced that it will host an expert panel on acromegaly and the results from its recently completed MPOWERED® Phase 3 clinical trial on Monday, November 30, 2020 at 11:00 am Eastern Time.

Read more from the original source:
Chiasma to Host an Expert Panel on Acromegaly and the MPOWERED® Phase 3 Trial Results

Read More...

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Sunday, November 22nd, 2020

CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced that management will participate in the following upcoming virtual investor conferences:

The rest is here:
Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Read More...

BioDelivery Sciences to Participate in the Piper Sandler 32nd Annual Healthcare Conference

Sunday, November 22nd, 2020

RALEIGH, N.C., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeff Bailey, Chief Executive Officer, and Terry Coelho, Chief Financial Officer, will participate in a fireside chat and 1x1 investor meetings at the Piper Sandler 32nd Annual Healthcare Conference.

Link:
BioDelivery Sciences to Participate in the Piper Sandler 32nd Annual Healthcare Conference

Read More...

Timber Pharmaceuticals Signs Waiver Agreement with Warrant Holders

Sunday, November 22nd, 2020

WOODCLIFF LAKE, NJ, Nov. 20, 2020 (GLOBE NEWSWIRE) -- NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it has signed waiver agreements with certain of its existing institutional investors.

Read more here:
Timber Pharmaceuticals Signs Waiver Agreement with Warrant Holders

Read More...

Auris Medical Launches Website for AM-301-focused Subsidiary, Altamira Medica

Sunday, November 22nd, 2020

Hamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced the launch of a dedicated website for its affiliate Altamira Medica Ltd. The website, www.altamiramedica.com, offers quick and easy access to information about the Company’s development of AM-301, a drug-free nasal spray intended for self-protection against risks from exposure to airborne viruses and allergens.

View post:
Auris Medical Launches Website for AM-301-focused Subsidiary, Altamira Medica

Read More...

Chalice Farms to Launch “Holiday in Color” Pre-Roll Packs, Festive Promotions through Holiday Season

Sunday, November 22nd, 2020

PORTLAND, Ore., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (CSE:GLH) (OTCQB:GLDFF) (“Golden Leaf” or the “Company”), a premier, consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, announces that Chalice Farms, a wholly owned subsidiary of Golden Leaf, will spread holiday cheer by launching a “Holiday in Color” pre-roll pack, along with weekly promotions and specials through the holidays, available now.

Continued here:
Chalice Farms to Launch “Holiday in Color” Pre-Roll Packs, Festive Promotions through Holiday Season

Read More...

LifeSci Acquisition II Corp. Announces Pricing of $75 Million Initial Public Offering

Sunday, November 22nd, 2020

NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) -- LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a blank check company targeting the biopharma sector, announced today that it priced its initial public offering of 7,500,000 shares at $10.00 per share. The shares will begin trading today on the NASDAQ Capital Market (“NASDAQ”) under the symbol “LSAQ.”

View original post here:
LifeSci Acquisition II Corp. Announces Pricing of $75 Million Initial Public Offering

Read More...

Zenith Files Notice of Annual and Special Meeting of Shareholders

Sunday, November 22nd, 2020

CALGARY, Alberta, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”) today announces the filing on SEDAR (www.sedar.com) of the Notice of Meeting and Management Information Circular (the “Notice”) related to its Annual and Special Meeting of Shareholders (the “Meeting”) being held on Tuesday, December 22, 2020 commencing at approximately 2:00 pm (MT).

Originally posted here:
Zenith Files Notice of Annual and Special Meeting of Shareholders

Read More...

Resverlogix Files Notice of Annual and Special Meeting of Shareholders

Sunday, November 22nd, 2020

CALGARY, Alberta, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the filing on SEDAR (www.sedar.com) of the Notice of Meeting and Management Information Circular (the “Notice”) related to its Annual and Special Meeting of Shareholders (the “Meeting”) being held on Tuesday, December 22, 2020 commencing at approximately 1:00 pm (MT).

Read the original post:
Resverlogix Files Notice of Annual and Special Meeting of Shareholders

Read More...

Page 11234


2020 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick